Content about IMS Health

April 11, 2012

Move over, Lipitor: There's a new top drug on the market, according to published reports.

NEW YORK — Move over, Lipitor: There's a new top drug on the market, according to published reports.

April 4, 2012

People ages 65 years and older reduced their volume of prescriptions, while those ages 19 to 25 years increased their use of prescription drugs as the healthcare-reform law allowed them to remain on their parents' insurance, according to a new report by IMS Health.

PARSIPPANY, N.J. — People ages 65 years and older reduced their volume of prescriptions, while those ages 19 to 25 years increased their use of prescription drugs as the healthcare-reform law allowed them to remain on their parents' insurance, according to a new report by IMS Health.

The report, "The Use of Medicines in the United States: Review of 2011," found that per capita spending on U.S. medicines grew by 0.5% as healthcare system spending reached $320 billion and new drug launches opened new treatment options for more than 20 million Americans.

March 28, 2012

A mild winter may be setting the stage for a particularly strong spring allergy season for sufferers allergic to tree pollens and mold. The incidence of seasonal allergy has been soft of late, but IMS Health is predicting a significant uptick in allergy sufferers in the coming months.

A mild winter may be setting the stage for a particularly strong spring allergy season for sufferers allergic to tree pollens and mold. The incidence of seasonal allergy has been soft of late, but IMS Health is predicting a significant uptick in allergy sufferers in the coming months.

March 28, 2012

Three companies have launched generic versions of a psychiatric drug made by AstraZeneca following a court decision turning down the Anglo-Swedish drug maker's request for an injunction against the Food and Drug Administration's approval of the generics.

NEW YORK — Three companies have launched generic versions of a psychiatric drug made by AstraZeneca following a court decision turning down the Anglo-Swedish drug maker's request for an injunction against the Food and Drug Administration's approval of the generics.

Dr. Reddy's Labs, Teva and Mylan announced Wednesday the launch of their respective versions of quetiapine fumarate tablets, generic formulations of AstraZeneca's Seroquel, in strengths ranging from 25 mg to 400 mg.

February 28, 2012

Lowering health costs will require a greater understanding of differences between two distinct groups of patients, according to a new study, which also noted a growing availability of specialty drugs for complex and chronic conditions outside the hospital.

PARSIPPANY, N.J. — Lowering health costs will require a greater understanding of differences between two distinct groups of patients, according to a new study, which also noted a growing availability of specialty drugs for complex and chronic conditions outside the hospital.

February 17, 2012

As of the beginning of February, the cough-cold season had yet to materialize and illness levels were only just beginning to climb. If that’s the case, then an expected illness peak in late February/early March would make the 2011-2012 cough, cold and flu season one of the later-peaking seasons in recent years.


As of the beginning of February, the cough-cold season had yet to materialize and illness levels were only just beginning to climb. If that’s the case, then an expected illness peak in late February/early March would make the 2011-2012 cough, cold and flu season one of the later-peaking seasons in recent years.


As of Jan. 21, overall incidence of upper respiratory illness this season was down 7.5% according to IMS Health, as compared with the 2010-2011 season.


February 17, 2012

As of early February, incidence of cough-cold and influenza still was relatively low, but the season has yet to peak and that means there could be demand for symptomatic relief through March.


As of early February, incidence of cough-cold and influenza still was relatively low, but the season has yet to peak and that means there could be demand for symptomatic relief through March.


“Fever is just starting to move,” noted Scott Hanslip, director of sales for IMS Consumer Health, in the first week of February. However, overall incidence of upper respiratory illness was down 7.5% from September through Jan. 21, 
according to IMS Health tracking.


February 17, 2012

A wet spring last year made for ideal allergen-
creating conditions heading into summer 2011 — the growth of ragweed and an increase in mold.

A wet spring last year made for ideal allergen-
creating conditions heading into summer 2011 — the growth of ragweed and an increase in mold. According to a Quest Diagnostics study published in 2011, sensitization to common ragweed has grown 15% nationally since 2000, while mold grew 12%. IMS Health projected a strong spring allergy season, especially across the north and northeast.


January 20, 2012

One issue that is unlikely to see resolution this year is the growing problem of drug shortages. As of October 2011, the Food and Drug Administration and the American Society of Health Systems Pharmacists found shortages of 168 drugs.

One issue that is unlikely to see resolution this year is the growing problem of drug shortages. As of October 2011, the Food and Drug Administration and the American Society of Health Systems Pharmacists found shortages of 168 drugs. According to healthcare analytics firm IMS Health, while this represents a small and highly concentrated portion of the overall drug market, it includes a number of critical drugs used to treat cancer, infections, cardiovascular disease, central nervous system disorders and pain.

January 20, 2012

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot.

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot. Because it’s the top-selling drug, well, ever — with 2010 sales well in excess of $7 billion in the United States alone — Lipitor’s loss of patent protection on Nov. 30, 2011, didn’t start or end the patent cliff but in many ways symbolized it.


December 13, 2011

Though they've been on the market for less than a month, the generic and authorized generic versions of Pfizer's cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.

NEW YORK — Though they've been on the market for less than a month, the generic and authorized generic versions of Pfizer's cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.

Citing an analysis of data from IMS Health by J.P. Morgan, The Wall Street Journal reported that Ranbaxy's generic atorvastatin calcium tablets and Watson Pharmaceuticals' authorized generic have claimed about 14.6% of prescription volume since their launch on Nov. 30.

December 5, 2011

With annual sales gaining on the $8 billion mark in the United States alone, according to IMS Health, Lipitor (atorvastatin) is the top-selling drug in the world, and the price markdown that Ranbaxy Labs’ launch (and subsequent generic launches) will bring, greatly will expand its accessibility. So it’s no surprise that it has attracted so much media attention over the past few weeks.

WHAT IT MEANS AND WHY IT'S IMPORTANT — With annual sales gaining on the $8 billion mark in the United States alone, according to IMS Health, Lipitor (atorvastatin) is the top-selling drug in the world, and the price markdown that Ranbaxy Labs’ launch (and subsequent generic launches) will bring, greatly will expand its accessibility. So it’s no surprise that it has attracted so much media attention over the past few weeks.

December 5, 2011

Following the settlement of a patent-litigation suit with Swiss drug maker Novartis over the patch Vivelle-Dot (estradiol transdermal system), a drug for treating symptoms of menopause, Mylan said it had received a patent license to begin selling its version of the drug in December 2013.


SUPPLIER NEWS — Following the settlement of a patent-litigation suit with Swiss drug maker Novartis over the patch Vivelle-Dot (estradiol transdermal system), a drug for treating symptoms of menopause, Mylan said it had received a patent license to begin selling its version of the drug in December 2013.


The Pittsburgh-based generic drug maker was the first to file for regulatory approval of the drug with the Food and Drug Administration, and as such will be entitled to 180 days of 
market exclusivity.


November 4, 2011

In the classic “Arabian Nights” tale of Aladdin and his magic lamp, the evil sorcerer who made Aladdin retrieve the lamp containing the genie attempts to get it back by tricking Aladdin’s wife into giving it to him by roaming through the streets offering to trade “new lamps for old.”


In the classic “Arabian Nights” tale of Aladdin and his magic lamp, the evil sorcerer who made Aladdin retrieve the lamp containing the genie attempts to get it back by tricking Aladdin’s wife into giving it to him by roaming through the streets offering to trade “new lamps for old.”


October 11, 2011

The Food and Drug Administration has approved Mylan’s promethazine hydrochloride tablets, a generic drug for treating allergies, in the 12.5-mg, 25-mg and 50-mg strengths.

SUPPLIER NEWS — The Food and Drug Administration has approved Mylan’s promethazine hydrochloride tablets, a generic drug for treating allergies, in the 12.5-mg, 25-mg and 50-mg strengths. Promethazine hydrochloride tablets, which are manufactured by several companies, had sales of about $42 million during the 12-month period ended in June, according to IMS Health.


October 10, 2011

The Federal Trade Commission has given Teva Pharmaceutical Industries the green light to acquire Frazer, Pa.-based drug maker Cephalon, but with some restrictions, Teva said.

JERUSALEM — The Federal Trade Commission has given Teva Pharmaceutical Industries the green light to acquire Frazer, Pa.-based drug maker Cephalon, but with some restrictions, Teva said.

Before it can complete the $6.8 billion deal, Teva must sell to Par Pharmaceutical Cos. its generic versions of two Cephalon drugs, namely generic versions of the cancer pain drug Actiq (fentanyl citrate) and the muscle relaxant drug Amrix (cyclobenzaprine), which have combined sales of $298 million per year, according to IMS Health.

September 22, 2011

A report commissioned by the Generic Pharmaceutical Association has drawn applause from manufacturers and a retail pharmacy industry group.

PITTSBURGH — A report commissioned by the Generic Pharmaceutical Association has drawn applause from manufacturers and a retail pharmacy industry group.

Generic drug maker Mylan, a member of the GPhA, praised the report, conducted by market research firm IMS Health, showing that the use of generic prescription drugs saved consumers, patients and healthcare providers more than $931 billion over the last decade.

September 12, 2011

It’s hard to disagree that generic drug companies have had a good run for the last several years. Branded drug companies developed a large number of drugs that proved highly effective at treating widespread medical conditions and became blockbusters, garnering billions of dollars in sales in the United States alone.

It’s hard to disagree that generic drug companies have had a good run for the last several years. Branded drug companies developed a large number of drugs that proved highly effective at treating widespread medical conditions and became blockbusters, garnering billions of dollars in sales in the United States alone. As patents on these blockbuster drugs have expired, they’ve provided generic manufacturers with enormous revenues, helping some to join the ranks of the world’s biggest drug companies.


September 12, 2011

At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


September 12, 2011

Healthcare information provider Wolters Kluwer Pharma has appointed Henry Prolog as its VP data strategy, acquisitions and services, the company said.

PHOENIX — Healthcare information provider Wolters Kluwer Pharma has appointed Henry Prolog as its VP data strategy, acquisitions and services, the company said.

The company said Prolog brought more than 25 years of sales, data contracts and marketing experience in the healthcare, technology and information services industries. Before Wolters Kluwer, Prolog worked for IMS Health, Siemens Medical, Fresenius USA and Verispan. Most recently, he was national director for channels at US Oncology in Houston.

August 18, 2011

With the global biosimilars market expected to expand nearly sixfold by the middle of the decade, market research firm IMS Health is launching a market-measurement tool for drug makers interested in getting into the space, the company said.

DANBURY, Conn. — With the global biosimilars market expected to expand nearly sixfold by the middle of the decade, market research firm IMS Health is launching a market-measurement tool for drug makers interested in getting into the space, the company said.

July 25, 2011

The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating deep vein thrombosis in patients undergoing knee or hip replacement surgery, a J&J subsidiary said.

SUPPLIER NEWS — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating deep vein thrombosis in patients undergoing knee or hip replacement surgery, a J&J subsidiary said. Janssen Pharmaceuticals announced the approval of Xarelto (rivaroxaban) tablets as a once-daily oral anticoagulant for DVT, a condition that could lead to pulmonary embolism.


June 27, 2011

The law targeting data mining in Vermont, along with laws in New Hampshire and Maine, would have forced drug companies to significantly change the way they market drugs to physicians had the Supreme Court allowed them to stand in the case of Sorrell, Attorney General of Vermont, et al. vs. IMS Health Inc., et al.

WHAT IT MEANS AND WHY IT'S IMPORTANT — The law targeting data mining in Vermont, along with laws in New Hampshire and Maine, would have forced drug companies to significantly change the way they market drugs to physicians had the Supreme Court allowed them to stand in the case of Sorrell, Attorney General of Vermont, et al. vs. IMS Health Inc., et al.

(THE NEWS: Supreme Court strikes down Rx data mining law. For the full story, click here.)

June 20, 2011

A generic drug maker has been granted approval from the Food and Drug Administration to manufacture its version of a urinary tract infection treatment.

SUPPLIER NEWS — A generic drug maker has been granted approval from the Food and Drug Administration to manufacture its version of a urinary tract infection treatment. Amneal Pharmaceuticals said that its nitrofurantoin oral suspension in the 25-mg/5-mL strength is the first-to-market generic version of Furadantin, made by Shionogi Pharma. Amneal will sell its generic in 8-oz. (230-mL) size bottles, the company said. Annual U.S. sales of nitrofurantoin oral suspension totaled $40 million for the year ended in January, according to IMS Health data.


June 20, 2011

The overall growth in drug spending for 2010 was 3.7%, according to the latest drug trend report by pharmacy benefit manager Medco Health Solutions. The lower increase 
was primarily due to higher rates of generic drug dispensing — more than 71% of drugs dispensed were generics.